Navigation Links
FierceBiotech Names Obesity Company Gelesis to 'Fierce 15' List of Top Emerging Biotech Companies
Date:9/15/2010

BOSTON, Sept. 15 /PRNewswire/ -- Gelesis, a Boston-based obesity company, announced today that it has been named to the FierceBiotech "Fierce 15" list, designating it as one of the top emerging biotech companies of 2010. The editors evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Gelesis was determined to be one of the "fiercest" with its novel approach to tackling obesity.

(Logo: http://photos.prnewswire.com/prnh/20080103/NETH025LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080103/NETH025LOGO)

John Carroll, FierceBiotech's Editor said "This is the first year FierceBiotech readers got a chance to directly nominate a company for the Fierce 15, and some of our most influential subscribers picked Gelesis as one of this year's most promising biotech companies in the industry."

"Gelesis has one of the most novel approaches to the complex challenge of obesity drug discovery that I have seen, both while running worldwide basic research at Merck, and subsequently in the biotech world,"  said Dr. Ben Shapiro, former Executive Vice President of Worldwide Basic and External Research at Merck and a Senior Partner at PureTech Ventures.

Obesity is the largest healthcare-related opportunity in the world, with close to two billion individuals being either overweight or obese according to the World Health Organization. No one has been successful at developing a safe and effective treatment for obesity despite the multi-billion dollar potential for such a product.  

Pharmaceutical attempts have been limited by modest efficacy and challenging safety profiles. Surgical intervention to reduce stomach volume mechanically is effective but the use of this invasive approach is limited to morbidly obese patients. Gelesis has taken an innovative biotech approach to the surgical volume reduction mechanism. The product concept involves the decrease of functional stomach and GI tract volume, with a patient swallowing capsules containing individual particles that swell to 100X their original size in the stomach environment. Delivered in a capsule, Gelesis technology was developed using safe food-grade components and was designed to work mechanically via several physiological mechanisms in the GI tract that induce satiation when one eats a full meal.  A video and animation of the Gelesis technology is available at www.gelesis.com/content/technology.

"Unlike other approaches, Gelesis' technology leverages the body's own physiological mechanisms to increase satiety and decrease hunger," said Yishai Zohar, Co-Founder and Chief Executive Officer of Gelesis. "Creating a technology that is completely non-invasive, uses safe food-grade components, and works through validated GI-localized mechanisms, was a breakthrough that took many years of research."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. FierceBiotech is the biotech industry's leading daily monitor - an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. A complete list of "Fierce 15" companies is available online at www.fiercebiotech.com.

Gelesis, Inc. is a Boston-based obesity company with two programs in clinical development. Gelesis was co-founded by PureTech Ventures and a scientific advisory board of renowned obesity experts and polymer scientists that includes: James Hill MD, Professor of Medicine & Pediatrics at the University of Colorado, and Past President of The Obesity Society (TOS); Lee M. Kaplan, MD, PhD, Director of Massachusetts General Hospital Weight Center and a leading researcher in gastric bypass surgery; Caroline Apovian, MD, Director of the Center for Nutrition and Weight Management at Boston Medical Center and leading obesity clinician; Allan Geliebter, PhD, Senior Attending Psychologist, St. Luke's-Roosevelt Hospital, pioneer of the gastric balloon; Luigi Ambrosio PhD, Head of the Institute for Composite & Biomaterials at the University of Naples; and Stephen Woods, PhD, Professor of Psychiatry and Director of the Obesity Research Center at the University of Cincinnati who discovered fundamental mechanisms of satiation.


'/>"/>
SOURCE Gelesis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
3. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
4. INC. 5000 Names ClinixMIS for Third Time
5. SL Industries Names Louis J. Belardi Chief Financial Officer
6. BayCare Health System Names Tim Thompson Chief Information Officer
7. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
8. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
9. Ikaria® Names New Chief Financial Officer
10. Codexis Names Peter Strumph SVP, Commercial Operations
11. Gentris Corporation Names New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... A stressful work ... work can also decrease overall productivity and performance in the workplace. The goal of ... During the last few weeks of April, Clearview Resolution Services will be shutting down ...
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... Ariz. (PRWEB) , ... April 25, 2017 , ... Emergency ... latest book of the Outlier Leadership Series, Outliers in Writing, set to publish in ... Professor of Emergency Medicine at the University of Arizona College of Medicine. He also ...
Breaking Medicine News(10 mins):